Peregrine Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PPHM)

$4.07 -0.13 (-3.10 %)
(As of 12/15/2017 04:57 AM ET)
Previous Close$4.20
Today's Range$3.94 - $4.18
52-Week Range$1.96 - $5.78
Volume348,400 shs
Average Volume311,802 shs
Market Capitalization$185.82 million
P/E RatioN/A
Dividend YieldN/A
Beta2.73

About Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Receive PPHM News and Ratings via Email

Sign-up to receive the latest news and ratings for PPHM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:PPHM
CUSIPN/A
Phone+1-714-5086000

Debt

Debt-to-Equity RatioN/A
Current Ratio1.46%
Quick Ratio1.10%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$57.63 million
Price / Sales3.19
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book4.28

Profitability

Trailing EPS($0.70)
Net Income$-28,150,000.00
Net Margins-39.23%
Return on Equity-52.55%
Return on Assets-24.77%

Miscellaneous

Employees323
Outstanding Shares45,210,000

Peregrine Pharmaceuticals (NASDAQ:PPHM) Frequently Asked Questions

What is Peregrine Pharmaceuticals' stock symbol?

Peregrine Pharmaceuticals trades on the NASDAQ under the ticker symbol "PPHM."

When did Peregrine Pharmaceuticals' stock split? How did Peregrine Pharmaceuticals' stock split work?

Peregrine Pharmaceuticals's stock reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Peregrine Pharmaceuticals stock prior to the reverse split would have 14 shares after the split.

How were Peregrine Pharmaceuticals' earnings last quarter?

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) posted its quarterly earnings results on Thursday, September, 8th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.07. The biopharmaceutical company had revenue of $5.61 million for the quarter, compared to the consensus estimate of $13.08 million. Peregrine Pharmaceuticals had a negative return on equity of 52.55% and a negative net margin of 39.23%. Peregrine Pharmaceuticals's revenue for the quarter was down 42.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.56) earnings per share. View Peregrine Pharmaceuticals' Earnings History.

When will Peregrine Pharmaceuticals make its next earnings announcement?

Peregrine Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Peregrine Pharmaceuticals.

Where is Peregrine Pharmaceuticals' stock going? Where will Peregrine Pharmaceuticals' stock price be in 2017?

1 equities research analysts have issued twelve-month price targets for Peregrine Pharmaceuticals' stock. Their predictions range from $10.00 to $10.00. On average, they expect Peregrine Pharmaceuticals' share price to reach $10.00 in the next year. View Analyst Ratings for Peregrine Pharmaceuticals.

Who are some of Peregrine Pharmaceuticals' key competitors?

Who are Peregrine Pharmaceuticals' key executives?

Peregrine Pharmaceuticals' management team includes the folowing people:

  • Paul J. Lytle, Chief Financial Officer (Age 48)
  • Mark R. Ziebell, Vice President, General Counsel, Corporate Secretary (Age 52)
  • Shelley P.M. Fussey Ph.D., Vice President - Intellectual Property (Age 50)
  • Joseph S. Shan, Vice President - Clinical & Regulatory Affairs (Age 43)
  • Joseph Carleone Ph.D., Director
  • Richard B. Hancock, Director
  • Joel McComb, Director
  • Gregory P. Sargen, Director
  • Mark R. Bamforth, Independent Director (Age 52)

Who owns Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include STAFFORD JOHN S III (7.30%), STAFFORD JOHN S III (7.30%), STAFFORD JOHN S III (7.30%), STAFFORD JOHN S III (7.30%), STAFFORD JOHN S III (7.30%) and Bandera Partners LLC (1.23%). View Institutional Ownership Trends for Peregrine Pharmaceuticals.

Who sold Peregrine Pharmaceuticals stock? Who is selling Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., Bandera Partners LLC, Brown Advisory Securities LLC, California Public Employees Retirement System, Commonwealth Equity Services Inc, Citadel Advisors LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Peregrine Pharmaceuticals.

Who bought Peregrine Pharmaceuticals stock? Who is buying Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Algert Global LLC, OxFORD Asset Management LLP and JPMorgan Chase & Co.. View Insider Buying and Selling for Peregrine Pharmaceuticals.

How do I buy Peregrine Pharmaceuticals stock?

Shares of Peregrine Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Peregrine Pharmaceuticals' stock price today?

One share of Peregrine Pharmaceuticals stock can currently be purchased for approximately $4.07.

How big of a company is Peregrine Pharmaceuticals?

Peregrine Pharmaceuticals has a market capitalization of $185.82 million and generates $57.63 million in revenue each year. The biopharmaceutical company earns $-28,150,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Peregrine Pharmaceuticals employs 323 workers across the globe.

How can I contact Peregrine Pharmaceuticals?

Peregrine Pharmaceuticals' mailing address is 14282 Franklin Ave, TUSTIN, CA 92780, United States. The biopharmaceutical company can be reached via phone at +1-714-5086000 or via email at [email protected]com.


MarketBeat Community Rating for Peregrine Pharmaceuticals (PPHM)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Peregrine Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Peregrine Pharmaceuticals (NASDAQ:PPHM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.83$6.83$7.00$7.00
Price Target Upside: 57.09% upside119.72% upside64.71% upside993.75% upside

Peregrine Pharmaceuticals (NASDAQ:PPHM) Consensus Price Target History

Price Target History for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals (NASDAQ:PPHM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Noble FinancialReiterated RatingBuyHighView Rating Details
9/13/2016Roth CapitalReiterated RatingNeutral$3.50N/AView Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$7.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Peregrine Pharmaceuticals (NASDAQ:PPHM) Earnings History and Estimates Chart

Earnings by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals (NASDAQ PPHM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018        
9/11/2017Q1 2018($0.12)($0.06)$15.22 million$27.08 millionViewN/AView Earnings Details
7/14/2017Q4 2017($0.07)($0.16)$22.57 million$17.90 millionViewN/AView Earnings Details
3/13/2017Q3 2017($0.21)($0.28)$14.02 million$10.75 millionViewN/AView Earnings Details
12/12/2016Q217($0.21)($0.14)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.28)($0.35)$13.08 million$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.21)($0.35)$15.80 million$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.49)($0.56)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.63)($0.49)$7.35 million$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.56)($0.56)$7.96 million$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.56)($0.49)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.56)($0.56)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.49)($0.49)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.42)($0.56)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.49)($0.42)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.42)($0.42)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.35)($0.35)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.35)($0.35)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.42)($0.42)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.49)($0.28)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.63)($0.56)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.77)($0.49)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.91)($0.70)ViewN/AView Earnings Details
3/9/2012($0.91)($0.91)ViewN/AView Earnings Details
12/12/2011($0.91)($1.12)ViewN/AView Earnings Details
9/9/2011($0.98)($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Peregrine Pharmaceuticals (NASDAQ:PPHM) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ PPHM)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Peregrine Pharmaceuticals (NASDAQ PPHM) News Headlines

Source:
DateHeadline
ETFs with exposure to Peregrine Pharmaceuticals, Inc. : December 14, 2017ETFs with exposure to Peregrine Pharmaceuticals, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:03 PM
Noble Financial Reiterates Buy Rating for Peregrine Pharmaceuticals (PPHM)Noble Financial Reiterates Buy Rating for Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - December 13 at 3:32 PM
Company News For Dec 13, 2017 - NasdaqCompany News For Dec 13, 2017 - Nasdaq
www.nasdaq.com - December 13 at 10:45 AM
Peregrine Pharmaceuticals (PPHM) Q2 2018 Results - Earnings Call Transcript - Seeking AlphaPeregrine Pharmaceuticals (PPHM) Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - December 13 at 10:45 AM
Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q2, 2018 By the Numbers : December 13, 2017Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q2, 2018 By the Numbers : December 13, 2017
finance.yahoo.com - December 13 at 10:44 AM
Pre-Open Movers 12/12: (PTI) (RPRX) (GLYC) Higher; (PPHM) (MARA) (CASY) Lower (more...) - StreetInsider.comPre-Open Movers 12/12: (PTI) (RPRX) (GLYC) Higher; (PPHM) (MARA) (CASY) Lower (more...) - StreetInsider.com
www.streetinsider.com - December 12 at 4:50 PM
After-Hours Stock Movers 12/11: (PTI) (KMG) Higher; (PPHM) (CASY) (OAS) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 12/11: (PTI) (KMG) Higher; (PPHM) (CASY) (OAS) Lower (more...) - StreetInsider.com
www.streetinsider.com - December 12 at 4:50 PM
Mid-Afternoon Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher - BenzingaMid-Afternoon Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher - Benzinga
www.benzinga.com - December 12 at 4:50 PM
Peregrine Pharmaceuticals (PPHM) Management on Q2 2018 Results - Earnings Call Transcript - Seeking AlphaPeregrine Pharmaceuticals' (PPHM) Management on Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - December 12 at 4:50 PM
7 Stocks To Watch For December 12, 2017 - Benzinga7 Stocks To Watch For December 12, 2017 - Benzinga
www.benzinga.com - December 12 at 4:50 PM
2 Stocks Fall Tuesday2 Stocks Fall Tuesday
finance.yahoo.com - December 12 at 4:50 PM
Edited Transcript of PPHM earnings conference call or presentation 11-Dec-17 9:30pm GMTEdited Transcript of PPHM earnings conference call or presentation 11-Dec-17 9:30pm GMT
finance.yahoo.com - December 12 at 10:50 AM
Peregrine Pharmaceuticals (PPHM) Posts  Earnings Results, Misses Expectations By $0.17 EPSPeregrine Pharmaceuticals (PPHM) Posts Earnings Results, Misses Expectations By $0.17 EPS
www.americanbankingnews.com - December 11 at 11:50 PM
Peregrine reports 2Q lossPeregrine reports 2Q loss
www.cnbc.com - December 11 at 4:43 PM
Peregrine Pharmaceuticals, Inc. to Host Earnings CallPeregrine Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - December 11 at 4:42 PM
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent DevelopmentsPeregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments
finance.yahoo.com - December 11 at 4:42 PM
Peregrine Pharmaceuticals (PPHM) Set to Announce Earnings on MondayPeregrine Pharmaceuticals (PPHM) Set to Announce Earnings on Monday
www.americanbankingnews.com - December 5 at 1:30 PM
Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017
finance.yahoo.com - December 4 at 4:33 PM
3 Drug Stocks That Soared This Week: Are They Buys? - Motley Fool3 Drug Stocks That Soared This Week: Are They Buys? - Motley Fool
www.fool.com - December 3 at 10:21 AM
Peregrine Pharmaceuticals (PPHM) Cut to Sell at ValuEnginePeregrine Pharmaceuticals (PPHM) Cut to Sell at ValuEngine
www.americanbankingnews.com - December 2 at 8:28 PM
Avid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business OperationsAvid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business Operations
finance.yahoo.com - November 29 at 10:27 AM
Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement AgreementPeregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement
finance.yahoo.com - November 28 at 10:37 AM
Peregrine Pharmaceuticals (PPHM) & Catalyst Biosciences (CBIO) Head to Head SurveyPeregrine Pharmaceuticals (PPHM) & Catalyst Biosciences (CBIO) Head to Head Survey
www.americanbankingnews.com - November 20 at 7:54 AM
Peregrine Pharmaceuticals Inc. (PPHM) Raised to Hold at Zacks Investment ResearchPeregrine Pharmaceuticals Inc. (PPHM) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - November 18 at 6:04 AM
Peregrine Announces Date of 2017 Annual Meeting of Stockholders - GlobeNewswire (press release)Peregrine Announces Date of 2017 Annual Meeting of Stockholders - GlobeNewswire (press release)
globenewswire.com - November 14 at 6:55 AM
Peregrine Announces Date of 2017 Annual Meeting of StockholdersPeregrine Announces Date of 2017 Annual Meeting of Stockholders
finance.yahoo.com - November 14 at 6:55 AM
Why Avistas CEO was recruited for Peregrines board - Triangle Business JournalWhy Avista's CEO was recruited for Peregrine's board - Triangle Business Journal
www.bizjournals.com - October 31 at 8:06 AM
Ronin Trading and SW Investment Management Release Presentation Highlighting Concerns with Board of Peregrine PharmaceuticalsRonin Trading and SW Investment Management Release Presentation Highlighting Concerns with Board of Peregrine Pharmaceuticals
finance.yahoo.com - October 31 at 8:06 AM
Peregrine Pharmaceuticals Inc. (PPHM) Director Acquires $225,000.00 in StockPeregrine Pharmaceuticals Inc. (PPHM) Director Acquires $225,000.00 in Stock
www.americanbankingnews.com - October 27 at 8:42 PM
Ronin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine PharmaceuticalsRonin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine Pharmaceuticals
finance.yahoo.com - October 27 at 11:10 AM
Peregrine Pharma (PPHM) Appoints Patrick Walsh to BoardPeregrine Pharma (PPHM) Appoints Patrick Walsh to Board
www.streetinsider.com - October 25 at 9:20 AM
ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 23, 2017ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 23, 2017
finance.yahoo.com - October 25 at 9:20 AM
Peregrine Pharma (PPHM) Appoints Patrick Walsh to Board - StreetInsider.comPeregrine Pharma (PPHM) Appoints Patrick Walsh to Board - StreetInsider.com
www.streetinsider.com - October 24 at 8:43 AM
Peregrine Pharma (PPHM) Appoints Mark Bamforth to Board - StreetInsider.comPeregrine Pharma (PPHM) Appoints Mark Bamforth to Board - StreetInsider.com
www.streetinsider.com - October 19 at 3:33 PM
Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid BioservicesPeregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices
finance.yahoo.com - October 19 at 3:33 PM
Contrasting Kadmon Holdings (KDMN) and Peregrine Pharmaceuticals (PPHM)Contrasting Kadmon Holdings (KDMN) and Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - October 18 at 8:20 PM
Critical Contrast: Peregrine Pharmaceuticals (PPHM) & Ocera Therapeutics (OCRX)Critical Contrast: Peregrine Pharmaceuticals (PPHM) & Ocera Therapeutics (OCRX)
www.americanbankingnews.com - October 18 at 4:24 PM
ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 12, 2017ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 12, 2017
finance.yahoo.com - October 13 at 8:14 AM
Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals - PR Newswire (press release)Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals - PR Newswire (press release)
www.prnewswire.com - October 11 at 6:40 AM
Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine PharmaceuticalsRonin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals
finance.yahoo.com - October 11 at 6:40 AM
Reviewing Peregrine Pharmaceuticals (PPHM) & The CompetitionReviewing Peregrine Pharmaceuticals (PPHM) & The Competition
www.americanbankingnews.com - October 8 at 2:24 PM
Earnings Review and Free Research Report: Peregrine Pharma’s Q1 Top-line Surged 383% Y-o-Y; Beat ProjectionsEarnings Review and Free Research Report: Peregrine Pharma’s Q1 Top-line Surged 383% Y-o-Y; Beat Projections
finance.yahoo.com - October 5 at 5:16 PM
Peregrine Pharmaceuticals Inc. (PPHM) Now Covered by Noble FinancialPeregrine Pharmaceuticals Inc. (PPHM) Now Covered by Noble Financial
www.americanbankingnews.com - September 29 at 6:00 PM
ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 26, 2017ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 26, 2017
finance.yahoo.com - September 26 at 7:10 PM
Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius ... - GlobeNewswire (press release)Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius ... - GlobeNewswire (press release)
globenewswire.com - September 25 at 5:16 PM
Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford FacilityAvid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford Facility
finance.yahoo.com - September 25 at 12:09 PM
Un-Spinning The Peregrine Pharmaceuticals Spin Zone - Seeking AlphaUn-Spinning The Peregrine Pharmaceuticals Spin Zone - Seeking Alpha
seekingalpha.com - September 22 at 7:01 PM
Comparing Peregrine Pharmaceuticals (PPHM) & The CompetitionComparing Peregrine Pharmaceuticals (PPHM) & The Competition
www.americanbankingnews.com - September 21 at 4:26 PM
Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition - GlobeNewswire (press release)Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition - GlobeNewswire (press release)
globenewswire.com - September 20 at 7:55 AM
Earnings Review and Free Research Report: Mesoblast Reported Q4 and Full Year FY17 ResultsEarnings Review and Free Research Report: Mesoblast Reported Q4 and Full Year FY17 Results
finance.yahoo.com - September 20 at 7:55 AM

SEC Filings

Peregrine Pharmaceuticals (NASDAQ:PPHM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Peregrine Pharmaceuticals (NASDAQ:PPHM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Peregrine Pharmaceuticals (NASDAQ PPHM) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.